FDA Approves First Standalone Robotic Blood-Draw Device

The U.S. Food and Drug Administration has granted marketing authorization to Vitestro for its Aletta system, the first standalone robotic device capable of drawing blood from a patient’s arm. The FDA’s approval marks a milestone in medical device innovation, allowing Aletta to be used in clinical settings without the need for a traditional phlebotomist.

Aletta operates by autonomously locating a vein, inserting a needle, and collecting the required volume of blood. The system is designed to reduce patient discomfort, improve consistency in sample collection, and free up healthcare staff for other tasks. Vitestro’s technology has undergone extensive clinical testing to demonstrate safety, accuracy, and reliability in a range of patient populations.

With this authorization, Vitestro becomes the first company to bring a fully automated blood‑draw device to the U.S. market, potentially reshaping routine phlebotomy procedures in hospitals, laboratories, and outpatient clinics.